Muscle Spasticity
Conditions
Brief summary
This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.
Interventions
DRUGonabotulinumtoxinA
onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Sponsors
Allergan
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment with onabotulinumtoxinA according to the decision of the physician for spasticity * Willingness to complete study questionnaires and answer study questions by phone or internet
Exclusion criteria
* Concurrent participation in a clinical trial for spasticity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Patients Reporting Satisfaction with Treatment | 5 Weeks |
| Percentage of Health Care Providers Reporting Satisfaction with Treatment | 12 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| Physical Functioning on a 5-Point Scale | 5 Weeks |
| Severity of Pain on an 11-Point Scale | 5 Weeks |
| Disability Assessment on a 4-Point Scale | 12 Weeks |
Countries
France, Germany, Italy, Spain, Taiwan, United Kingdom, United States
Outcome results
None listed